Molecular analysis of residual tumors treated with MK591 revealed reduced levels of ERK, cyclin D1 and Aurora kinase B proteins, suggesting that targeting 5-Lox by MK591 or similar agents could be a potent strategy for inhibiting pancreatic tumor growth. The gene discussed is CCND1; the disease is pancreatic neoplasm.